Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.
Rui You, Gui-Qiong Xu, Xi Ding...
https://pubmed.ncbi.nlm.nih.gov/41667193/Actively Recruiting
Led by Sun Yat-sen University · Updated on 2020-09-28
388
Participants Needed
6
Research Sites
104 weeks
Total Duration
Researchers are evaluating the addition of PD-1 treatment to chemo-radiotherapy for high-risk patients with nasopharyngeal carcinoma. This study is a multicenter, open-label, randomized clinical trial comparing outcomes between patients receiving combined PD-1 therapy with chemo-radiotherapy and those receiving chemo-radiotherapy alone. The goal is to see if the combined approach can reduce disease progression and improve survival. Participants are randomly assigned to one of two groups. One group receives three cycles of gemcitabine and cisplatin induction chemotherapy followed by concurrent chemo-radiotherapy with camrelizumab given intravenously during radiotherapy and continued for one year after. The other group receives the same chemotherapy and chemo-radiotherapy without camrelizumab. Radiotherapy is delivered using specific dosing schedules across several target volumes. During the study, participants undergo regular assessments including monitoring for disease progression, survival, treatment-related complications, and quality of life using standardized questionnaires. The primary outcome measured is progression-free survival over three years, with secondary outcomes including overall survival, metastasis-free survival, relapse-free survival, and treatment safety. The total study period extends up to three years for follow-up and evaluation.
CONDITIONS
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
M
Ming-Yuan Chen, MD, PhD
R
Rui You, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Sun Yat-sen University
Lead Sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 9 weeks
Participants receive 3 cycles of gemcitabine plus cisplatin chemotherapy before starting chemo-radiotherapy.
3 chemotherapy cycles, 1 cycle every 3 weeks
Duration - Approximately 6 to 7 weeks
Participants undergo concurrent chemo-radiotherapy with cisplatin chemotherapy and intensity-modulated radiotherapy (IMRT). Participants in the experimental arm also receive camrelizumab during this period.
Concurrent chemotherapy cycles and daily radiotherapy sessions over 33 fractions; 2 cycles of camrelizumab for experimental arm
Duration - Up to 1 year
Participants in the experimental arm receive camrelizumab treatment for up to 1 year after the end of radiotherapy to maintain immune response.
Camrelizumab administered every 3 weeks
Duration - Up to 3 years
Participants are monitored for treatment outcomes and safety, including progression-free survival and survival quality assessments.
Regular follow-up visits as per study schedule
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Rui You, Gui-Qiong Xu, Xi Ding...
https://pubmed.ncbi.nlm.nih.gov/41667193/Sun Yat-sen University
Lead Sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Collaborating Sponsor